In Vivo Efficacy of a Novel Oxazolidinone Compound in Two Mouse Models of Infection | Zendy

Charles Gill | Zendy; George K. Abruzzo | Zendy; Amy Flattery | Zendy; Andrew S. Misura | Zendy; Ken Bartizal | Zendy; Emily Hickey | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vivo Efficacy of a Novel Oxazolidinone Compound in Two Mouse Models of Infection

Author(s) -

Charles Gill,

George K. Abruzzo,

Amy Flattery,

Andrew S. Misura,

Ken Bartizal,

Emily Hickey

Publication year - 2007

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01567-06

Subject(s) - linezolid , staphylococcus aureus , in vivo , staphylococcal infections , microbiology and biotechnology , methicillin resistant staphylococcus aureus , medicine , antibacterial agent , micrococcaceae , antibiotics , biology , bacteria , vancomycin , genetics

A novel oxazolidinone, AM 7359, was evaluated in two mouse models ofStaphylococcus aureus infection. AM 7359 and linezolid were equally efficacious in a methicillin-susceptibleS. aureus organ burden model and a methicillin-resistantS. aureus localized infection model. However, AM 7359 was eightfold more efficacious than linezolid against a linezolid- and methicillin-resistantS. aureus strain in this localized (thigh) infection model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research